Premium
Complications Associated with CDDP Intraperitoneal Chemotherapy
Author(s) -
Adachi Susumu,
Noda Tsuneo,
Ito Kimihiko,
Kiyozuka Yasuhiko,
Itani Yoshio,
Shintani Masashi,
Hisanaga Hiroyasu,
Umekage Hideshi,
Nakayama Masahiro,
Fujita Masayuki
Publication year - 1994
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1994.tb00413.x
Subject(s) - medicine , catheter , surgery , laparotomy , complication , chemotherapy , port (circuit theory) , ovarian cancer , cisplatin , anesthesia , adverse effect , cancer , electrical engineering , engineering
As CDDP‐ip is known to affect intraperitoneal tumors directly, and reduce CDDP associated adverse reactions, it has been used not only for ovarian cancer but other intraperitoneal tumors. However ip chemotherapy requires catheter placement at the time of laparotomy. We investigated the complications of catheters as an intraperitoneal administration route. The subjects were 84 patients, 39 with temporary catheters and 45 with an implantable port and catheter system. Twenty‐seven percent of the temporary catheter patients experienced complications‐infection 8%, inflow obstruction 3%, leakage 5%, extrusion 8%, and severe pain 3%. Furthermore, a total of 22% of patients with an implantable port and catheter system experienced complications‐inflow obstruction 9%, infection 2%, leakage 4%, and extrusion 7%. Fortunately, no serious complications were observed at our institutions, and the complication incidence seemed lower compared to that of other institutions.